Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
Trial details
- Registry ID
- NCT07477366
- Phase
- Phase 2
The FDA approved rituximab (Rituxan) on 26 Nov 1997.
Drug identity checked against registry records
Also recorded as Rituxan
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366 | IBRX | Phase 2 | Not yet recruiting | 2027-12Estimated |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006 | NRIX | Phase 1, Phase 2 | Recruiting | 2033-05Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1997-11-26Day | rituximab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA103705", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["RITUXAN"], "active_ingredients": ["RITUXIMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19971126", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |